Novartis and University of California-Berkeley Researchers Estimate $93 Billion Wasted Yearly Across Healthcare Stakeholders, Propose Value-Based Pricing System
Researchers at the University of California-Berkeley and Novartis note that $93 billion is wasted yearly in addressing healthcare utilization management, [...]
What Will Happen to Novartis Cholesterol Drug?
Novartis drug inclisiran wasn’t reviewed on time by the FDA—largely because of COVID-19 travel restrictions. Now, the company seeks to [...]
ICER Releases Draft Evidence Report on Treatments for High Cholesterol
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report evaluating the comparative clinical effectiveness and [...]
ICER Plans Review of Treatments for High Cholesterol
The Institute for Clinical and Economic Review (ICER) announced plans to review Novartis' inclisiran and Esperion Therapeutics' Nexletol for the [...]
FiercePharma Offering Live Updates to Coronavirus
FiercePharma is offering live updates of the coronavirus, as well as the goings-on in the pharmaceutical industry amid the outbreak. [...]
Massachusetts to Pay for Zolgensma on One Condition: It Must Work
Massachusetts' Medicaid program, MassHealth, has inked a conditional deal for Novartis' $2 million one-time spinal muscular atrophy (SMA) gene therapy, [...]
ICER Recommends Major Price Reductions for New Sickle Cell Drugs
The Institute for Clinical and Economic Review (ICER) in a draft report recommended significant price cuts for two sickle cell [...]
